Richard Hague

Richard is an accomplished biotechnology executive and board member with extensive experience in the development and commercialization of innovative therapies focused mainly on the orthopedic and wound care markets. Richard is currently the President and CEO of PolarityTE, a regenerative medicine company developing its lead autologous cell based product for skin regeneration.

Before joining PolarityTE, Richard held executive roles with several leading healthcare companies, which included Genzyme and later Sanofi (post Sanofi's acquisition of Genzyme) where he was VP/General Manager of the company’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard was involved in the launch of the first autologous cell therapy for cartilage repair and the first HA injectable for the management of osteoarthritis pain. Richard’s broad experience includes raising capital in the public markets, licensing and M&A transactions, and successful product launches via the CBER and CDRH regulatory pathways. Richard is a graduate of the University of Connecticut’s School of Business.